ASCO-CIM NEUROBLASTOMA CABA

1. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

2. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

3. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

4. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

5. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

6. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

7. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

8. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

9. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

10. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

11. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

12. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

13. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

14. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

15. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

16. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

17. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

18. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

19. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

20. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

21. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

22. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

23. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

24. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

25. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

26. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

27. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

28. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

29. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

30. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

31. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

32. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

33. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting
LESTAURTINIB CEP 701

34. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

35. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

36. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

37. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

38. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

39. Crizotinib
The first drug to be approved by the U.S. Food and Drug
Administration (FDA) for treatment of ALK-rearranged cancers
was crizotinib, an orally bioavailable ATP-competitive 2,4-
pyrimidinediamine derivative [PF2341066; Pfizer Inc. ].
Crizotinib binds to the inactive conformation of ALK and has
shown striking efficacy against ALK-rearranged tumors such as
NSCLC and inflammatory myofibroblastic tumor. In early-
phase clinical testing, the overall response rate was 57% in a
population of 82 patients with EML4-ALK–positive NSCLC

40. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

41. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

42. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

43. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

44. [TITLE]
Presented By Garrett M. Brodeur, MD at 2013 ASCO Annual Meeting

45. Monoclonal antibody against the tumor-associated
disialoganglioside GD2, ch14.18 has activity against
neuroblastoma and that such activity is enhanced when
ch14.18 is combined with granulocyte–macrophage colony-
stimulating factor (GM-CSF) or interleukin-2. We conducted a
study to determine whether adding ch14.18, GM-CSF, and
interleukin-2 to standard isotretinoin therapy after intensive
multimodal therapy would improve outcomes in high-risk
neuroblastoma.

46. [TITLE]
Presented By Paul M. Sondel, MD, PhD at 2013 ASCO Annual Meeting

47. [TITLE]
Presented By Paul M. Sondel, MD, PhD at 2013 ASCO Annual Meeting

48. KIR and HLA Genotypes Are Associated with Disease
Progression and Survival following Autologous Hematopoietic
Stem Cell Transplantation for High-Risk Neuroblastoma
• NK cells exhibit cytotoxicity against neuroblastoma. Gene
polymorphisms governing NK cell function, therefore, may
influence prognosis. Two highly polymorphic genetic loci
instrumental in determining NK cell responses encode the NK
cell killer immunoglobulin-like receptors (KIR) and their class
I human leukocyte antigen (HLA) ligands. We hypothesized
that patients with a “missing ligand” KIR-HLA compound
genotype may uniquely benefit from autologous
hematopoietic stem cell transplantation (HSCT).

49. [TITLE]
Presented By Paul M. Sondel, MD, PhD at 2013 ASCO Annual Meeting

50. [TITLE]
Presented By Paul M. Sondel, MD, PhD at 2013 ASCO Annual Meeting

51. [TITLE]
Presented By Paul M. Sondel, MD, PhD at 2013 ASCO Annual Meeting

52. [TITLE]
Presented By Paul M. Sondel, MD, PhD at 2013 ASCO Annual Meeting